Background/aims To evaluate the status of myelin oligodendrocyte glycoprotein antibodies (MOG-IgG) in chronic relapsing inflammatory optic neuropathy (CRION) and investigate its different clinical characteristics and prognosis.
Methods Patients diagnosed with CRION were recruited by the Neuro-ophthalmology Department of the Chinese People's Liberation Army General Hospital from December 2015 to April 2017. Based on antibody status, they were assigned to either the MOG-CRION or seronegative-CRION groups.
Results A total of 33 patients (38 eyes) were assessed and divided into the following groups: 22 (66.7%) MOG-CRION and 11 (33.3%) seronegative-CRION. The ratio of female to male was 1:1, and 81.8% of total CRION patients were adults (≥18 years). A total of 29 eyes (76.3%) showed severe visual loss (<20/200) during the first optic neuritis episode, and 37 eyes (72.5%) demonstrated good visual recovery (>20/40) during the final follow-up. The mean onset age of MOG-CRION patients was 28 ± 16 years (range 6–62), which was significantly younger than that of seronegative-CRION (45 ± 12 years, range 22–59) (p=0.029). The intraorbital and canalicular segments were highly involved in the orbital MRI of CRION patients. During the final follow-up, MOG-CRION patients had more bilateral involvement (p=0.008) and higher annualised relapse rates compared with the seronegative-CRION patients (p=0.019).
Conclusion CRION was predominantly found in adults with unilateral ON and exhibited a higher rate of seropositive MOG-IgG. MOG-CRION, which may be a disparate subtype of MOG-IgG-induced demyelinating disease that needs further investigation, was found in younger patients at onset, with more bilateral involvement and more relapse tendency.
- optic nerve
- visual pathway
Statistics from Altmetric.com
Contributors HL and HZ: study design, manuscript draft and revision, data collection and statistical analysis. QX and JW: study design and manuscript revision. SW: study design, correspondence and manuscript revision.
Funding This work is supported by the 863 Plan Biological and Medical Technology project “Development of equipments in diagnosis and visual function evaluation for optic neuritis”, China (NO: 2015AA020511).
Competing interests None declared.
Patient consent for publication Obtained.
Ethics approval The Institutional Review Board at the Chinese PLAGH.
Provenance and peer review Not commissioned; externally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.